1.240USD+3.33%Mkt Cap: 85.25M USDP/E: —Last update: 2026-05-26
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non…
Industry Peers
Medical Devices151.38BUSDP/E 24.3
119.84BUSDP/E 36.2
86.12BUSDP/E 24.2
54.95BSEKP/E 101.9
53.92BSEKP/E 22.9
52.13BDKKP/E 22.1
50.54BUSDP/E 47.4
39.31BEURP/E 18.6
Indicators:|
Key Statistics
Company
Market Cap85.25M USD
Enterprise Value158.78M USD
Revenue (TTM)151.64M USD
Gross Profit72.31M USD
Net Income (TTM)-39.00M USD
Revenue/Share2.231 USD
Last Price1.240 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees658
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.53
PEG—
EV/EBITDA-6.16
EV/Revenue1.05
P/S0.55
P/B6.23
EPS (TTM)-0.54
EPS (Forward)-0.34
52W Range
0.800011% of range4.850
52W High4.850 USD
52W Low0.8000 USD
Profitability
Gross Margin48.48%
Oper. Margin-26.11%
EBITDA Margin-17.00%
Profit Margin-26.15%
ROE-174.27%
ROA-27.55%
Growth
Revenue Growth7.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-20.37M USD
CapEx (TTM)801.00K USD
FCF Margin-3.02%
FCF Yield-5.38%
Net Debt72.17M USD
Net Debt/EBITDA-2.80
Balance Sheet
Debt/Equity4.04
Current Ratio1.67
Quick Ratio1.03
Book Value/Sh0.1910 USD
Cash/Share0.1900 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.333 USD
Target Range3.000 USD – 7.000 USD
# Analysts3
Ownership
Shares Out.69.59M
Float30.56M
Insiders32.19%
Institutions59.86%
Short Interest
Short Ratio5.0d
Short % Float30.48%
Short % Out.15.05%
Shares Short10.47M
Short (prev mo.)9.38M
Technical
SMA 501.502 (-17.5%)
SMA 2002.072 (-40.2%)
Beta1.13
S&P 52W Chg28.31%
Avg Vol (30d)2.58M
Avg Vol (10d)3.49M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—